HSICNasdaqWholesale-Medical, Dental & Hospital Equipment & SuppliesFiscal year ends December 26
HENRY SCHEIN INC
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 4, 2026
$83.97−2.41 (-2.79%)
Close on Oct 19, 2026
- Market cap
- $9.61B
- P/E (TTM)
- 24.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
31.1%+3.3 pts over 5 years
Operating margin
5.0%−0.3 pts over 5 years
Net margin
3.0%−1.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.0% | +1.4% | +5.4% | +2.2% | |
| Gross profit | +2.2% | +2.3% | +7.8% | +3.2% | |
| Operating income | +5.2% | -4.4% | +4.1% | -1.2% | |
| Net income | +2.1% | -9.6% | -0.3% | -1.8% | |
| EPS, diluted | +7.2% | -5.8% | +3.0% | +1.4% | |
| Free cash flow | -18.1% | +4.2% | +0.8% | +0.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 17.9% | 12.7% | 12.0% | |
| Return on assets | 7.6% | 5.4% | 3.7% | |
| Current ratio | 1.44 | 1.66 | 1.38 | |
| Debt to equity | 0.28 | 0.21 | 0.96 | |
| Net debt to EBITDA | 0.78× | 0.39× | 3.06× | |
| Interest coverage | 24.2× | 13.0× | 4.4× | |
| Inventory turnover | 5.3× | 5.0× | 4.8× | |
| Capex to revenue | 0.6% | 0.5% | 1.1% | |
| Diluted shares | 164M | 143M | 122M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Henry Schein generated $3.37B from operations and spent $2.98B on capital expenditure, dividends and share buybacks. 20% of that went back into the business.
Generated
$3.37B
Used
$2.98B
Capital expenditure$609.00M20%Dividends$00%Share buybacks$2.37B80%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.0%
×Asset turnover1.23×
×Equity multiplier3.23×
=Return on equity, FY202512.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3.0% | 1.23× | 3.23× | 12.0% |
| FY2024 | 3.1% | 1.22× | 2.95× | 11.1% |
| FY2023 | 3.4% | 1.29× | 2.70× | 11.7% |
| FY2022 | 4.3% | 1.48× | 2.49× | 15.7% |
| FY2021 | 5.1% | 1.53× | 2.40× | 18.6% |
| FY2020 | 4.0% | 1.36× | 2.35× | 12.7% |
| FY2019 | 7.0% | 1.28× | 2.63× | 23.3% |
| FY2018 | 5.7% | 1.15× | 2.83× | 18.6% |
| FY2017 | 4.6% | 1.21× | 2.62× | 14.5% |
| FY2016 | 4.4% | 1.73× | 2.35× | 17.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$398.00M
- Cash generatingOperating cash flow above zero$712.00M
- Return on assets improvedROA up on the prior year3.7% → 3.9%
- Earnings backed by cashOperating cash flow above net income$712.00M vs $398.00M
- Less leverageLong-term debt to assets fell17.9% → 20.6%
- Better liquidityCurrent ratio rose1.42 → 1.38
- No dilutionShare count did not rise128M → 122M
- Gross margin improvedGross margin up on the prior year31.69% → 31.14%
- More efficientAsset turnover rose1.20 → 1.29